This result was particularly significant for patients cotreated with megestrolacetate.
2
Ongoing studies have been designed to better study the appetite-enhancing effects of megestrolacetate.
3
Aim: To study the impurity in the drug megestrolacetate.
4
Our objective was to evaluate the antiemetic ability of megestrolacetate in patients receiving chemotherapy.
5
Results: Two new epimers were isolated from the mother liquid of the drug megestrolacetate.
6
Like the cortisones, megestrolacetate actually increases appetite, can increase risk of respiratory infections, and may suppress adrenal function.
7
This study determined whether an EPA supplement-administered alone or with megestrolacetate (MA)-was more effective than MA.
8
The incidence of adrenal suppression was affected by age, performance status, stage, and use of megestrolacetate in univariate analysis.
9
The positive dose-response effect observed for megestrolacetate on appetite stimulation supports both the prestudy hypothesis and findings in the literature.
10
The data demonstrate a positive dose-response effect for megestrolacetate on appetite stimulation (p = 0.02).
11
Interestingly, ten of 12 patients who had developed disease progression while on standard-dose megestrolacetate therapy had objective response or stabilization on the higher dose.
12
Megestrolacetate might be a new antiemetic option for chemotherapy.
13
Megestrolacetate was well tolerated in this group of patients with advanced malignant disease.
14
Megestrolacetate (MA) is used to stimulate appetite in children with cancer, but it can impair adrenal function and cause adrenal insufficiency.
15
Megestrolacetate (Megace, Bristol-Myers Squibb Co.) proves so far the most effective pharmacological preparation which improves anorexia and cachexia in severely ill patients.